Abiant

Abiant, Inc., a company based in Illinois specializing in advanced bio-imaging technology aimed at accelerating and improving drug development and disease diagnosis, announced the successful completion of a $600,000 private placement. The lead investor, Heartland Angels, an angel network focused on early-stage technologies, co-hosted this round with Kettering Medical Center and other participants. Abiant has established partnerships with large pharmaceutical companies and academic collaborators. The company has obtained an exclusive license from New York University School of Medicine for image processing technology that enables early and accurate identification of dementia. Proprietary image analysis methods and software are used to provide sensitive biomarkers of drug effects and disease progression. Imaging information, including biochemical, functional, and structural measurements, can be utilized to accelerate or reduce risks in drug development and disease treatment decisions. The company's key focus areas include the central nervous system, oncology, and inflammation.